The clinical-stage biopharmaceutical company developing psychedelic and non-psychedelic compounds for various mental health indications, has recently announced the closing of its USD 157mn Series D financing round.
The round was led by existing investors Apeiron Investment Group (family office of ATAI founder Christian Angermayer), Thiel Capital and new investor Woodline Partners LP, a US based investment firm that is focused on equity investments in global healthcare and technology sectors.
Proceeds from financing will allow accelerated expansion and development of the diverse drug candidate pipeline and provide the necessary runway to continue its current clinical advancements, as well as scale its experienced team.
“This marks a monumental moment for ATAI; we continue on our mission challenging the current way mental health conditions are treated. We have become better equipped than ever to accelerate the development of more efficacious treatments,” said Florian Brand, CEO & co-founder of ATAI. “With support from our investors, we are determined to improve care and innovate.”
QC·Ventures is proud investor since the first financing round and is convinced that ATAI will continue to drive innovation and revolutionize mental health treatment before their anticipated IPO later this year.